跳至主要内容
临床试验/NCT06345690
NCT06345690进行中(未招募)不适用

VIA Disc NP Registry 3.0

VIVEX Biologics, Inc.24 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2024年2月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
500
试验地点
24
主要终点
Numeric Pain Rating Scale (NPRS)

研究概览

简要总结

Registry is to observe and trend patterns of care and outcomes for patients treated with VIA Disc NP.

详细描述

The Registry is intended to collect data for patients having received treatment with VIA Disc NP.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol
  • 18 years of age or older
  • Literate, able to speak and read English, and able to complete questionnaires independently
  • Subject received a VIA Disc NP injection with 1 or more levels within 90 days of the baseline visit.

排除标准

  • Participant did not receive VIA Disc NP injection
  • Participant is pregnant (self-reported, no special study pregnancy testing needed).
  • Any contraindications as noted in the VIA Disc NP Instructions for Use
  • Previous treatment with VIA Disc NP

研究组 & 干预措施

VIA Disc NP

Patients meeting study criteria receiving Vivex VIA Disc NP injection as treatment

干预措施: VIA Disc NP (Other)

结局指标

主要结局

Numeric Pain Rating Scale (NPRS)

时间窗: 1, 3, 6, & 12 months

Change in Numeric Rating Scale (NRS) scores. Eleven point pain scale used for patient self-reporting of back pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable).

Oswestry Disability Index (ODI)

时间窗: 1, 3, 6, & 12 months

Change in scores from Oswestry Disability Index (ODI). An index comprising of ten categories of function to quantify disability due to back pain.

Patient Satisfaction

时间窗: 1, 3, 6, & 12 months

Patient reported assessment of treatment regarding their experience with the procedure. Four different responses, which range from Not at all satisfied (worst) to Extremely Satisfied (best).

Frequency of Pain Medication Use

时间窗: 1, 3, 6, & 12 months

Assesses the frequency and type of pain medication administered to participants at baseline and follow-up visits scheduled at 1, 3, 6, and 12 months. Data will be collected to track changes in pain medication usage over time.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (24)

Loading locations...

相似试验

终止
不适用
VIA Disc NP RegistryDiscogenic PainBack PainBack Pain, Low
NCT04652687VIVEX Biologics, Inc.83
已完成
不适用
The Management of Schizophrenia in Clinical Practice (MOSAIC)Schizophrenia
NCT01746134Genentech, Inc.557
已完成
不适用
VASCADE ANTEGRADE-PVD Post-Market RegistrySurgical Wound
NCT02948257Cardiva Medical, Inc.52
已完成
不适用
The Registry to Observe Clinical Outcomes of Patients with High-risk Metastatic Hormone-naive Prostate Cancer in JapaHigh-risk metastatic hormone-naive prostate cancer
JPRN-UMIN000037127Janssen Pharmaceutical K.K.102
招募中
不适用
AnovaOS Network Powered Patient RegistryInfectious DiseaseNeoplasmsDiseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89)Endocrine, Nutritional and Metabolic Diseases (E00-E89)Mental and Behavioural DisordersDiseases of the Nervous SystemDiseases of the Eye and AdnexaDiseases of the Ear and Mastoid ProcessDiseases of the Circulatory SystemDiseases of the Respiratory SystemDiseases of the Digestive SystemDiseases of the Skin and Subcutaneous TissueDiseases of the Musculoskeletal System and Connective TissueDiseases of the Genitourinary SystemPregnancy, Childbirth and the PuerperiumCertain Conditions Originating in the Perinatal PeriodCongenital Malformations, Deformations and Chromosomal Abnormalities (Q00-Q99)Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere ClassifiedInjury, Poisoning and Certain Other Consequences of External CausesExternal Causes of Morbidity and MortalityFactors Influencing Health Status and Contact With Health Services
NCT05013944Anova Enterprises, Inc100,000
VIA Disc NP Registry 3.0 | 临床试验